CD33-Targeting CAR T Cells for Acute Myeloid Leukemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as surgery, radiation therapy, and chemotherapy, are inadequate for effectively targeting CD33-expressing cancers, and immunotherapy has not fully harnessed the potential of the human immune system for cancer therapy.
Innovation Solution
Development of recombinant antibodies, including anti-CD33 monoclonal antibodies and chimeric antigen receptors (CARs), that selectively bind to CD33-expressing cancer cells, engaging T-cells to destroy these cells, and genetically modifying immune effector cells to express these receptors for targeted cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (surgery, radiation, chemotherapy) are used, then cancer can be treated, but they are inadequate for effectively targeting CD33-expressing cancers
Solution Approach 1:
The patent introduces anti-CD33 antibodies as intermediary molecules that specifically bind to CD33-expressing cancer cells. These antibodies serve as mediators between the immune system and cancer cells, enabling targeted recognition and destruction of malignancies while sparing healthy tissues that do not express CD33.
Solution Approach 2:
The patent employs parameter changes by modifying antibody structures (creating chimeric, humanized, and recombinant variants) to optimize binding affinity and specificity for CD33. Additionally, the patent modifies immune effector cells by introducing chimeric antigen receptors (CARs) with specific signaling domains to enhance their ability to recognize and destroy CD33-expressing cancers.
2Adaptability or versatility
If immunotherapy is used to harness the immune system for cancer treatment, then cancer therapy potential is expanded, but the full potential of the immune system has not been realized
Solution Approach 1:
The patent enables the immune system to serve itself by engineering chimeric antigen receptors (CARs) that combine antibody binding domains with T-cell signaling domains. This self-service mechanism allows modified immune effector cells to autonomously recognize CD33-expressing cancer cells and activate cytotoxic responses without requiring external stimulation or complex conditioning protocols.
Solution Approach 2:
The patent creates composite molecular structures by fusing antibody variable domains (for antigen recognition) with T-cell receptor signaling domains (for activation). These chimeric molecules combine the specificity of antibodies with the potent cytotoxic capability of T-cells, creating a composite therapeutic agent that leverages the strengths of both immune components.
3Measurement precision
If recombinant antibodies and chimeric antigen receptors are developed to selectively bind CD33-expressing cancer cells, then specific targeting is achieved, but complex molecular engineering is required
Solution Approach 1:
The patent segments the complex immune recognition and activation process into distinct functional domains: an antigen-binding domain (from antibodies) that provides specificity, a transmembrane domain that anchors the receptor, and a signaling domain that triggers cellular activation. This segmentation allows each component to be optimized independently and assembled into functional chimeric antigen receptors.
Solution Approach 2:
The patent creates universal chimeric antigen receptor designs that can be applied across different cancer types expressing CD33. By using standardized signaling domains (such as CD3ζ, CD28, or 4-1BB) combined with the CD33-specific antibody binding domain, the same basic CAR structure can target various malignancies including acute myeloid leukemia and myelodysplastic syndromes, reducing the need for de novo engineering for each application.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enables specific targeting and destruction of CD33-expressing cancer cells, potentially leading to effective treatment of malignancies like myelodysplastic syndrome and acute myeloid leukemia by leveraging the immune system's ability to recognize and attack cancer cells.
Implementation Method 1
anti-CD33 antibodies are disclosed herein that are capable of selectively binding CD33-expressing cancers
Data Source
AI summary
Disclosed are compositions and methods for targeted treatment of CD33-expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill CD33-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a CD33-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs. Also disclosed are multivalent antibodies are disclosed that are able to engage T-cells to destroy CD33-expressing malignant cells.